FDA extends Ranbaxy ban
January 27, 2014Manufacturing and Production, Sales and Marketing API, FDA, Ranbaxy, toansa
India-based generic manufacturer Ranbaxy Laboratories has been dealt a further blow as the US regulator has banned more of its …
Shire replaces retiring chairman with former banker
January 24, 2014Sales and Marketing Organogenesis, Shire, dermagraft, emmens, kilsby
Susan Kilsby is to be the new chairman at Shire and steps into Matthew Emmens’s role as he retires from …
Elderly denied cancer treatment on NHS
January 24, 2014Sales and Marketing Cancer, Macmillan, NCIN, NHS, elderly
A UK charity is warning the NHS not to write off older cancer patients as ‘too old’ for treatment. With …
Mail backs down over NICE ‘champagne perks’ attack
January 24, 2014Medical Communications, Sales and Marketing Daily Mail, NHS, NICE, UK, spending
The Daily Mail newspaper has backed down on an article it published earlier this month, which alleged that staff at …
NHS consults on loosening controls for Viagra
January 23, 2014Sales and Marketing DH, ED, NHS, Pfizer, Sildenafil, viagra
The Department of Health is looking to make cheaper generic versions of Pfizer’s Viagra more widely available to patients with …
Danish government: ‘Sue pharma firms’
January 23, 2014Sales and Marketing Actavis, Danish, Denmark, Lundbeck, celexa
A senior figure in Denmark’s government has said that local authorities should take legal action against pharma firms which put …
Novartis may axe 1,000 jobs in Diovan wake
January 23, 2014Manufacturing and Production, Sales and Marketing Coartem, Diovan, Novartis, cuts
Novartis will shut down a plant in New York State that made heart drug Diovan and malaria treatment Coartem as …
Biotec Services appoints US head
January 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Clinical trials services firm Biotec Services International is looking to expand its presence in the US with the appointment of …
J&J profits up amid drug gains
January 23, 2014Sales and Marketing FDA, J&J, JJ, Remicade, Zytiga, olysio, q4
Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …
ABPI: NHS must explain drugs take-up
January 22, 2014Sales and Marketing ABPI, NHS, NICE, Whitehead
The ABPI has called on the NHS to explain what it says is the ‘substantial variation’ in NHS patients’ access …
J&J tops social media leaderboard
January 22, 2014Medical Communications, Research and Development, Sales and Marketing Facebook, IMS, J&J, JJ, Twitter, You Tube, social media
A new report has found that Johnson & Johnson is the most engaged pharma company when it comes to using …
Director appointments at Hanover
January 22, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hanover, harrison
Comms and PR consulting firm Hanover has announced senior management changes within its healthcare practice. Andrew Harrison (pictured) takes on …
NICE recommends Aubagio
January 22, 2014Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya
NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …
EU regulator recommended 81 medicines in 2013
January 21, 2014CHMP, EC, EU, FDA, US, rare diseases
Last year the Committee for Medicinal Products for Human Use (CHMP) recommended 81 medicines for marketing approval, compared with just …
Emergent plans to triple anthrax vaccine production
January 21, 2014Manufacturing and Production Emergent BioSolutions, FDA, anthrax, biothrax
Emergent BioSolutions is planning a major expansion of manufacturing capacity for its anthrax vaccine BioThrax to meet the biodefense objectives …
Herceptin biosimilar set for Indian market
January 21, 2014Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab
Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …
AbbVie advances oncology drug
January 21, 2014Research and Development, Sales and Marketing AbbVie, DNA, oncology, veliparib
AbbVie has begun a Phase III trial of its investigational compound veliparib in women with early-stage, triple-negative breast cancer. This …
Roche schizophrenia drug fails
January 21, 2014Research and Development, Sales and Marketing Roche, biopertin, schizophrenia
Roche’s investigational schizophrenia drug bitopertin has failed to help patients with the disorder’s negative symptoms when pitted against placebo. Two …
Manufacturing news in brief
January 21, 2014Manufacturing and Production BASF, Heidelberg CSAT, Markem-Imaje, SEPIPROD and Micro-Sphere/NanoMaterials Technology, SPL, Shenzhen Hepalink
Shenzhen Hepalink buys SPL and Markem-Imaje takes over Heidelberg CSAT, plus a new science park in the UK and updates …
Novasep adds president to complete its executive team
January 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nieuwenhove, Novasep
Thierry Van Nieuwenhove has joined contract manufacturing organisation Novasep as president of its Synthesis business unit. Educated as a bio-engineer, Van …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
